

Topic Not Assigned A Bill or Rule Number

2021-2022 Legislative Session

Development, drafting or introduction of a proposal relating to

Biosimilar substitution for interchangeables, as deemed by the FDA

Action Intended To Affect: Both Legislative matter and rule

[AbbVie, Inc.](#)

Notified Date: 10/31/2017